Concepedia

Jakob Obermüller

JO

2

Publications

27

Citations

2

H-Index

2019

Active since

Affiliations

Oncopeptides (Sweden)(Current)

Harvard University

Dana-Farber Cancer Institute

Jakob Obermüller is an author at Oncopeptides (Sweden) specializing in health sciences, radiation oncology, and cancer research.

Top concepts

HealthMedicineOncologyHematologyImmunologyCancer ResearchClinical TrialsPharmacotherapyRadiation Oncology

Publications per year

2019–2021

2

Publications

2

ANCHOR (OP-104): Updated Efficacy and Safety from a Phase 1/2 Study of Melflufen and Dexamethasone Plus Bortezomib or Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to an IMiD or a Proteasome Inhibitor (PI)

Enrique M. Ocio, Yvonne A. Efebera, Miquel Granell et al. · Blood · 2019 · 14 citations

Melflufen plus dexamethasone in relapsed/refractory multiple myeloma: long‐term survival follow‐up from the Phase II study O‐12‐M1

Sara Bringhen, Peter M. Voorhees, Torben Plesner et al. · British Journal of Haematology · 2021 · 13 citations · Full text

Melphalan Flufenamide, Immunology, Pharmacotherapy +16

Rows per page

1–2 of 2